To date, two types of target drugs are promising in advanced ccRCC treatment: inhibitors of VEGF (bevacizumab) or angiogenesis tyrosine kinase inhibitors such as Axitinib, Sunitinib, Pazopanib and Sorafenib and inhibitors of the mTOR signaling pathway (Everolimus and Temsirolimus) [110]. Here, VEGFA is linked to nonpapillary renal cell carcinoma.